Title,Decision,Decision_Date
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer,Conditional,2025-02-19
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer,Conditional,2025-02-19
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over,Rejected,2025-02-12
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over,Conditional,2025-02-12
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over,Conditional,2025-02-12
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy,Approved,2025-02-12
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer,Approved,2025-02-05
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment,Conditional,2025-02-05
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease,Approved,2025-01-23
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal),Rejected,2025-01-22
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours,Approved,2025-01-22
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over,Approved,2025-01-16
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal),Rejected,2025-01-15
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal),Rejected,2025-01-15
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer,Approved,2025-01-15
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban,Conditional,2021-05-12
Tebentafusp for treating advanced uveal melanoma,Approved,2025-01-09
Tirzepatide for managing overweight and obesity,Conditional,2024-12-23
Ublituximab for treating relapsing multiple sclerosis,Conditional,2024-12-18
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments,Approved,2024-12-11
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal),Rejected,2024-12-11
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer,Conditional,2024-12-04
Bevacizumab gamma for treating wet age-related macular degeneration,Conditional,2024-12-04
Eplontersen for treating hereditary transthyretin-related amyloidosis,Approved,2024-11-27
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer,Approved,2024-11-20
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis,Conditional,2024-11-20
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over,Approved,2024-11-20
Elafibranor for previously treated primary biliary cholangitis,Approved,2024-11-14
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer,Approved,2024-11-13
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments,Approved,2024-11-13
Avapritinib for treating advanced systemic mastocytosis,Approved,2024-11-06
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria,Conditional,2024-10-23
"Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia",Approved,2024-10-23
Belzutifan for treating tumours associated with von Hippel-Lindau disease,Approved,2024-10-16
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension,Conditional,2024-10-02
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments,Approved,2024-09-25
"Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",Approved,2024-09-17
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal),Rejected,2024-09-12
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over,Approved,2024-09-11
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over,Conditional,2024-09-11
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion,Approved,2024-09-11
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,Approved,2024-09-11
Iptacopan for treating paroxysmal nocturnal haemoglobinuria,Approved,2024-09-04
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment,Approved,2024-09-04
Vibegron for treating symptoms of overactive bladder syndrome,Approved,2024-09-04
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma,Approved,2024-08-29
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer,Approved,2021-10-20
Risankizumab for treating moderately to severely active ulcerative colitis,Conditional,2024-08-22
Relugolix for treating hormone-sensitive prostate cancer,Approved,2024-08-14
Linzagolix for treating moderate to severe symptoms of uterine fibroids,Conditional,2024-08-14
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal),Rejected,2024-08-08
Abaloparatide for treating osteoporosis after menopause,Conditional,2024-08-07
Burosumab for treating X-linked hypophosphataemia in adults,Approved,2024-08-07
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy,Rejected,2024-07-29
"Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis",Approved,2024-07-24
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B,Approved,2024-07-24
Tenecteplase for treating acute ischaemic stroke,Approved,2024-07-24
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over,Conditional,2024-07-10
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal),Rejected,2024-07-10
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma,Conditional,2024-07-03
Selective internal radiation therapies for treating hepatocellular carcinoma,Conditional,2021-03-31
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy,Approved,2024-06-19
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal),Rejected,2024-06-13
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma,Rejected,2024-06-12
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation,Approved,2024-06-05
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal),Rejected,2024-06-05
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal),Rejected,2024-05-29
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over,Approved,2024-05-29
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal),Rejected,2024-05-29
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal),Rejected,2024-05-22
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis,Approved,2007-08-22
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis,Approved,2014-05-28
Cladribine for treating relapsing–remitting multiple sclerosis,Conditional,2019-12-19
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration,Rejected,2008-08-27
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia,Conditional,2013-11-27
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion,Conditional,2013-05-22
Atogepant for preventing migraine,Conditional,2024-05-15
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma,Conditional,2024-05-15
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under,Approved,2024-05-15
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments,Approved,2024-05-08
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19,Rejected,2024-05-08
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over,Conditional,2024-05-01
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma,Rejected,2018-09-03
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal),Rejected,2024-04-30
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2024-04-25
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal),Rejected,2024-04-24
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma,Conditional,2024-04-10
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,Approved,2024-04-03
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal),Rejected,2024-03-28
"Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy",Approved,2024-03-28
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal),Rejected,2024-03-28
Ritlecitinib for treating severe alopecia areata in people 12 years and over,Approved,2024-03-27
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis,Conditional,2024-03-27
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal),Rejected,2024-03-27
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms,Conditional,2024-03-20
"Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19",Conditional,2023-03-29
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema,Conditional,2024-03-13
Dupilumab for treating moderate to severe prurigo nodularis,Rejected,2024-03-13
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over,Approved,2024-03-11
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments,Conditional,2024-03-06
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations,Approved,2024-02-21
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over,Conditional,2024-02-07
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over,Conditional,2024-02-07
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer,Approved,2024-02-07
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments,Conditional,2024-01-31
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments,Approved,2024-01-31
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal),Rejected,2024-01-30
"Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Approved,2024-01-17
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer,Approved,2024-01-10
Targeted-release budesonide for treating primary IgA nephropathy,Conditional,2023-12-20
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal),Rejected,2023-12-20
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal),Rejected,2023-12-20
Empagliflozin for treating chronic kidney disease,Conditional,2023-12-20
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes,Rejected,2023-12-19
Risdiplam for treating spinal muscular atrophy,Conditional,2021-12-16
"Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer",Conditional,2023-12-13
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal),Rejected,2023-12-07
Secukinumab for treating moderate to severe hidradenitis suppurativa,Conditional,2023-12-06
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal),Rejected,2023-11-30
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal),Rejected,2023-11-29
Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms,Conditional,2023-11-29
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal),Rejected,2023-11-23
Zanubrutinib for treating chronic lymphocytic leukaemia,Conditional,2023-11-22
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments,Rejected,2023-11-15
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction,Approved,2023-11-01
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine,Rejected,2023-11-01
Ranibizumab for treating diabetic macular oedema,Rejected,2013-02-27
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable,Approved,2023-10-25
Tirzepatide for treating type 2 diabetes,Conditional,2023-10-25
Baricitinib for treating severe alopecia areata,Rejected,2023-10-25
Mirikizumab for treating moderately to severely active ulcerative colitis,Conditional,2023-10-25
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal),Rejected,2023-10-19
Rimegepant for treating migraine,Conditional,2023-10-18
Tofacitinib for treating active ankylosing spondylitis,Conditional,2023-10-18
Ruxolitinib for treating polycythaemia vera,Approved,2023-10-18
Daridorexant for treating long-term insomnia,Conditional,2023-10-18
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments,Approved,2023-10-17
Bimekizumab for treating axial spondyloarthritis,Conditional,2023-10-11
Pegunigalsidase alfa for treating Fabry disease,Conditional,2023-10-04
Bimekizumab for treating active psoriatic arthritis,Conditional,2023-10-04
"Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency",Approved,2023-09-20
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy,Conditional,2023-09-06
Semaglutide for managing overweight and obesity,Conditional,2023-03-08
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease,Conditional,2023-08-15
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer,Conditional,2023-07-26
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal),Rejected,2023-07-13
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer,Rejected,2023-07-12
Rimegepant for preventing migraine,Conditional,2023-07-05
"Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy",Conditional,2023-07-05
Deucravacitinib for treating moderate to severe plaque psoriasis,Conditional,2023-06-28
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction,Approved,2023-06-21
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer,Approved,2023-06-21
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer,Approved,2023-06-21
Upadacitinib for previously treated moderately to severely active Crohn’s disease,Conditional,2023-06-21
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal),Rejected,2023-06-20
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer,Conditional,2023-06-14
Tixagevimab plus cilgavimab for preventing COVID-19,Rejected,2023-06-14
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma,Rejected,2023-06-07
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy,Conditional,2023-06-07
Bulevirtide for treating chronic hepatitis D,Conditional,2023-06-07
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over,Conditional,2023-06-07
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma,Conditional,2023-06-06
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal),Rejected,2023-06-06
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia,Conditional,2023-05-31
Mosunetuzumab for treating relapsed or refractory follicular lymphoma,Rejected,2023-05-31
Risankizumab for previously treated moderately to severely active Crohn's disease,Conditional,2023-05-17
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2023-05-17
Difelikefalin for treating pruritus in people having haemodialysis,Approved,2023-05-17
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy,Approved,2023-05-10
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,Approved,2023-05-10
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments,Rejected,2023-05-03
Voclosporin with mycophenolate mofetil for treating lupus nephritis,Approved,2023-05-03
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma,Rejected,2023-05-03
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal),Rejected,2023-05-03
Tezepelumab for treating severe asthma,Conditional,2023-04-20
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal),Rejected,2023-04-06
Finerenone for treating chronic kidney disease in type 2 diabetes,Conditional,2023-03-23
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer,Approved,2023-03-22
Eptinezumab for preventing migraine,Conditional,2023-03-01
Cannabidiol for treating seizures caused by tuberous sclerosis complex,Conditional,2023-03-01
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma,Conditional,2023-03-01
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,Conditional,2023-02-28
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma,Conditional,2023-02-22
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal),Rejected,2023-02-16
Vutrisiran for treating hereditary transthyretin-related amyloidosis,Approved,2023-02-15
"Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",Conditional,2023-02-08
Regorafenib for previously treated metastatic colorectal cancer,Approved,2023-02-08
Upadacitinib for treating active non-radiographic axial spondyloarthritis,Conditional,2023-02-01
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,Approved,2023-02-01
Somatrogon for treating growth disturbance in children and young people aged 3 years and over,Approved,2023-02-01
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,Conditional,2023-02-01
Maribavir for treating refractory cytomegalovirus infection after transplant,Conditional,2023-01-18
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal),Rejected,2023-01-16
"Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma",Approved,2023-01-11
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma,Conditional,2023-01-11
Upadacitinib for treating moderately to severely active ulcerative colitis,Approved,2023-01-04
Avatrombopag for treating primary chronic immune thrombocytopenia,Approved,2022-12-15
Cabozantinib for previously treated advanced hepatocellular carcinoma,Conditional,2022-12-14
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,Rejected,2022-12-14
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,Approved,2022-12-14
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments,Approved,2022-12-14
Esketamine nasal spray for treatment-resistant depression,Rejected,2022-12-14
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal),Rejected,2022-12-01
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal),Rejected,2022-11-29
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal),Rejected,2022-11-29
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal),Rejected,2022-11-29
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal),Rejected,2022-11-24
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal),Rejected,2022-11-24
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2022-11-22
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal),Rejected,2022-11-22
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal),Rejected,2022-11-16
"Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids 
 (terminated appraisal)",Rejected,2022-11-16
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal),Rejected,2022-11-02
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma,Conditional,2022-10-26
"Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Conditional,2022-10-26
Pembrolizumab for adjuvant treatment of renal cell carcinoma,Conditional,2022-10-19
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids,Approved,2022-10-19
Zanubrutinib for treating Waldenstrom’s macroglobulinaemia,Conditional,2022-10-19
Fostamatinib for treating refractory chronic immune thrombocytopenia,Conditional,2022-10-19
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal),Rejected,2022-10-12
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy,Approved,2022-10-05
Ozanimod for treating moderately to severely active ulcerative colitis,Conditional,2022-10-05
Upadacitinib for treating active ankylosing spondylitis,Conditional,2022-09-30
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer,Approved,2022-09-28
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis,Conditional,2022-09-21
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal),Rejected,2022-09-21
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal),Rejected,2022-09-14
Dexamethasone intravitreal implant for treating diabetic macular oedema,Conditional,2022-09-14
Brolucizumab for treating diabetic macular oedema,Conditional,2022-08-31
Avalglucosidase alfa for treating Pompe disease,Conditional,2022-08-24
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies,Conditional,2022-08-17
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma,Conditional,2022-08-17
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2022-08-10
"Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",Conditional,2022-08-10
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence,Conditional,2022-08-10
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer,Rejected,2022-08-03
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors,Conditional,2022-08-03
"Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis",Conditional,2022-08-03
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal),Rejected,2022-07-27
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease,Approved,2022-07-20
"Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",Approved,2022-07-20
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2022-07-13
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides,Conditional,2022-07-13
Belimumab for treating lupus nephritis (terminated appraisal),Rejected,2022-07-13
Roxadustat for treating symptomatic anaemia in chronic kidney disease,Conditional,2022-07-13
Fenfluramine for treating seizures associated with Dravet syndrome,Conditional,2022-07-08
Teduglutide for treating short bowel syndrome,Conditional,2022-06-30
Faricimab for treating diabetic macular oedema,Conditional,2022-06-29
Faricimab for treating wet age-related macular degeneration,Conditional,2022-06-29
"Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",Conditional,2022-06-29
Cemiplimab for treating advanced cutaneous squamous cell carcinoma,Conditional,2022-06-29
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,Conditional,2022-06-22
Venetoclax for treating chronic lymphocytic leukaemia,Approved,2022-06-15
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal),Rejected,2022-06-15
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal),Rejected,2022-06-08
Diroximel fumarate for treating relapsing–remitting multiple sclerosis,Conditional,2022-06-08
Ibrutinib for treating Waldenstrom’s macroglobulinaemia,Rejected,2022-06-08
Filgotinib for treating moderately to severely active ulcerative colitis,Approved,2022-06-01
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal),Rejected,2022-05-25
Romosozumab for treating severe osteoporosis,Conditional,2022-05-25
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations,Conditional,2022-05-18
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy,Conditional,2022-05-11
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,Conditional,2022-04-27
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,Conditional,2022-04-27
"Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",Conditional,2022-04-20
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal),Rejected,2022-04-20
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma,Conditional,2022-04-13
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,Conditional,2022-03-30
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal),Rejected,2022-03-30
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma,Approved,2022-03-24
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,Conditional,2022-03-16
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal),Rejected,2022-03-09
Empagliflozin for treating chronic heart failure with reduced ejection fraction,Conditional,2022-03-09
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea,Rejected,2022-03-09
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea,Rejected,2022-03-09
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria,Conditional,2022-03-09
Dapagliflozin for treating chronic kidney disease,Conditional,2022-03-09
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,Conditional,2022-02-23
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer,Conditional,2022-02-09
"Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)",Rejected,2022-02-09
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable,Conditional,2022-02-02
Fremanezumab for preventing migraine,Conditional,2022-02-02
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,Conditional,2022-02-02
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma,Conditional,2022-02-02
Ponesimod for treating relapsing–remitting multiple sclerosis,Conditional,2022-02-02
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2022-02-02
Palforzia for treating peanut allergy in children and young people,Approved,2022-02-02
Sodium zirconium cyclosilicate for treating hyperkalaemia,Conditional,2019-09-04
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,Conditional,2022-01-19
Cabotegravir with rilpivirine for treating HIV-1,Approved,2022-01-05
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy,Conditional,2022-01-05
Belimumab for treating active autoantibody-positive systemic lupus erythematosus,Conditional,2021-12-15
Cenobamate for treating focal onset seizures in epilepsy,Conditional,2021-12-15
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome,Conditional,2021-12-15
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal),Rejected,2021-12-08
Dupilumab for treating severe asthma with type 2 inflammation,Conditional,2021-12-08
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders,Conditional,2021-12-01
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal),Rejected,2021-12-01
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer,Conditional,2021-11-17
Nintedanib for treating progressive fibrosing interstitial lung diseases,Approved,2021-11-17
Upadacitinib for treating moderate rheumatoid arthritis,Conditional,2021-11-10
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal),Rejected,2021-11-10
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer,Conditional,2021-10-28
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer,Conditional,2021-10-28
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable,Conditional,2021-10-27
Tofacitinib for treating juvenile idiopathic arthritis,Conditional,2021-10-20
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,Conditional,2021-10-20
Berotralstat for preventing recurrent attacks of hereditary angioedema,Conditional,2021-10-20
Secukinumab for treating moderate to severe plaque psoriasis in children and young people,Conditional,2021-10-07
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal),Rejected,2021-10-06
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia,Conditional,2021-10-06
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal),Rejected,2021-09-29
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal),Rejected,2021-09-29
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2021-09-22
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2021-09-22
Midostaurin for treating advanced systemic mastocytosis,Conditional,2021-09-22
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria,Conditional,2021-09-22
"Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Conditional,2021-09-15
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer,Rejected,2021-09-08
Bimekizumab for treating moderate to severe plaque psoriasis,Conditional,2021-09-01
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,Conditional,2021-08-25
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome,Approved,2008-03-26
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma,Conditional,2021-08-18
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,Rejected,2021-08-18
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency,Conditional,2021-07-28
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal),Rejected,2021-07-21
Ixekizumab for treating axial spondyloarthritis,Conditional,2021-07-21
Secukinumab for treating non-radiographic axial spondyloarthritis,Conditional,2021-07-21
"Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed",Rejected,2021-07-14
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal),Rejected,2021-07-14
Enzalutamide for treating hormone-sensitive metastatic prostate cancer,Approved,2021-07-07
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy,Conditional,2021-07-07
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation,Approved,2013-02-27
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation,Approved,2015-09-23
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis,Approved,2021-06-23
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency,Conditional,2021-06-23
Ravulizumab for treating atypical haemolytic uraemic syndrome,Approved,2021-06-23
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer,Conditional,2021-06-15
Ozanimod for treating relapsing–remitting multiple sclerosis,Rejected,2021-06-09
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer,Approved,2021-06-02
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal),Rejected,2021-05-26
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal),Rejected,2021-05-26
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,Conditional,2021-05-26
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria,Approved,2021-05-19
Ofatumumab for treating relapsing multiple sclerosis,Conditional,2021-05-19
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal),Rejected,2021-05-19
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,Rejected,2021-04-28
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia,Conditional,2021-04-28
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma,Conditional,2021-04-28
Avelumab for treating metastatic Merkel cell carcinoma,Conditional,2018-04-11
Acalabrutinib for treating chronic lymphocytic leukaemia,Conditional,2021-04-21
Avelumab for untreated metastatic Merkel cell carcinoma,Conditional,2021-04-21
Anakinra for treating Still’s disease,Approved,2021-03-31
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal),Rejected,2021-03-31
"Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Conditional,2021-03-31
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,Conditional,2021-03-17
Erenumab for preventing migraine,Conditional,2021-03-10
"Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer",Conditional,2021-03-10
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma,Conditional,2021-03-03
Baricitinib for treating moderate to severe atopic dermatitis,Conditional,2021-03-03
Filgotinib for treating moderate to severe rheumatoid arthritis,Conditional,2021-02-24
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma,Approved,2021-02-24
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal),Rejected,2021-02-24
Dapagliflozin for treating chronic heart failure with reduced ejection fraction,Conditional,2021-02-24
"Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",Conditional,2021-02-17
"Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)",Rejected,2021-02-17
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal),Rejected,2021-02-17
Trabectedin for the treatment of advanced soft tissue sarcoma,Approved,2010-02-24
Mepolizumab for treating severe eosinophilic asthma,Conditional,2021-02-03
Brolucizumab for treating wet age-related macular degeneration,Conditional,2021-02-03
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,Conditional,2021-01-27
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer,Conditional,2021-01-06
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma,Conditional,2020-12-16
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura,Conditional,2020-12-16
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia,Conditional,2020-12-09
Liraglutide for managing overweight and obesity,Conditional,2020-12-09
Upadacitinib for treating severe rheumatoid arthritis,Conditional,2020-12-09
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer,Conditional,2020-11-25
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,Conditional,2020-11-25
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal),Rejected,2020-11-25
Drug-eluting stents for the treatment of coronary artery disease,Conditional,2008-07-23
Guidance on the use of coronary artery stents,Rejected,2003-10-22
Siponimod for treating secondary progressive multiple sclerosis,Conditional,2020-11-18
Carfilzomib for previously treated multiple myeloma,Conditional,2020-11-18
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma,Conditional,2020-11-18
Galcanezumab for preventing migraine,Conditional,2020-11-18
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy,Conditional,2020-10-21
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer,Conditional,2020-10-14
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer,Conditional,2020-10-14
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma,Rejected,2020-09-30
Naldemedine for treating opioid-induced constipation,Approved,2020-09-30
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma,Conditional,2020-09-23
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal),Rejected,2020-09-09
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal),Rejected,2020-09-02
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal),Rejected,2020-09-02
Avelumab with axitinib for untreated advanced renal cell carcinoma,Conditional,2020-09-02
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma,Approved,2020-08-12
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia,Conditional,2020-08-12
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer,Conditional,2020-08-12
Entrectinib for treating NTRK fusion-positive solid tumours,Approved,2020-08-12
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant,Approved,2020-08-05
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer,Conditional,2020-07-01
"Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",Conditional,2020-07-01
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal),Rejected,2020-06-30
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal),Rejected,2020-06-30
Eculizumab for treating refractory myasthenia gravis (terminated appraisal),Rejected,2020-06-30
Ranibizumab for treating diabetic retinopathy (terminated appraisal),Rejected,2020-06-30
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure,Approved,2020-06-24
Ustekinumab for treating moderately to severely active ulcerative colitis,Conditional,2020-06-17
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer,Conditional,2020-06-10
Larotrectinib for treating NTRK fusion-positive solid tumours,Approved,2020-05-27
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer,Approved,2020-05-13
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab,Conditional,2020-05-13
Lenalidomide with rituximab for previously treated follicular lymphoma,Approved,2020-04-07
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal),Rejected,2020-03-04
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis,Approved,2020-02-19
Patiromer for treating hyperkalaemia,Conditional,2020-02-13
Sotagliflozin with insulin for treating type 1 diabetes,Conditional,2020-02-12
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal),Rejected,2020-01-15
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure,Approved,2020-01-08
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome,Conditional,2019-12-18
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome,Conditional,2019-12-18
"Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",Conditional,2019-11-20
Pentosan polysulfate sodium for treating bladder pain syndrome,Conditional,2019-11-13
Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal),Rejected,2019-10-30
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal),Rejected,2019-10-30
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease,Approved,2019-10-17
Lanadelumab for preventing recurrent attacks of hereditary angioedema,Conditional,2019-10-16
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea,Conditional,2019-10-09
Idelalisib for treating refractory follicular lymphoma,Rejected,2019-10-02
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal),Rejected,2019-09-25
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2019-09-25
Benralizumab for treating severe eosinophilic asthma,Conditional,2019-03-06
Risankizumab for treating moderate to severe plaque psoriasis,Conditional,2019-08-21
Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal),Rejected,2019-08-14
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer,Conditional,2019-08-14
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis,Conditional,2019-07-31
Letermovir for preventing cytomegalovirus disease after a stem cell transplant,Conditional,2019-07-31
Nusinersen for treating spinal muscular atrophy,Conditional,2019-07-24
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity,Conditional,2019-07-24
Bisphosphonates for treating osteoporosis,Rejected,2017-08-09
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality,Conditional,2014-09-24
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies,Conditional,2009-06-18
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib,Conditional,2019-06-26
Lenalidomide plus dexamethasone for previously untreated multiple myeloma,Conditional,2019-06-26
Ocrelizumab for treating primary progressive multiple sclerosis,Conditional,2019-06-12
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes,Conditional,2019-06-05
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer,Approved,2019-06-05
Enzalutamide for hormone-relapsed non-metastatic prostate cancer,Rejected,2019-05-15
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma,Conditional,2019-04-24
Certolizumab pegol for treating moderate to severe plaque psoriasis,Conditional,2019-04-17
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal),Rejected,2019-04-17
Tildrakizumab for treating moderate to severe plaque psoriasis,Conditional,2019-04-17
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes,Conditional,2019-03-27
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib,Conditional,2019-03-20
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal),Rejected,2019-03-20
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer,Conditional,2019-03-20
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal),Rejected,2019-03-13
Cochlear implants for children and adults with severe to profound deafness,Rejected,2019-03-07
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia,Conditional,2019-02-27
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma,Conditional,2019-02-27
"Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",Conditional,2019-02-27
"Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)",Rejected,2019-02-20
Regorafenib for previously treated advanced hepatocellular carcinoma,Conditional,2019-01-09
Darvadstrocel for treating complex perianal fistulas in Crohn’s disease,Rejected,2019-01-09
Lenvatinib for untreated advanced hepatocellular carcinoma,Conditional,2018-12-19
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia,Conditional,2018-12-19
Vandetanib for treating medullary thyroid cancer,Rejected,2018-12-12
Decitabine for untreated acute myeloid leukaemia (terminated appraisal),Rejected,2018-12-05
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal),Rejected,2018-12-05
Tofacitinib for moderately to severely active ulcerative colitis,Conditional,2018-11-28
Padeliporfin for untreated localised prostate cancer,Rejected,2018-11-21
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia,Conditional,2018-11-14
Eltrombopag for treating chronic immune thrombocytopenia,Conditional,2013-07-24
Romiplostim for the treatment of chronic immune thrombocytopenia,Conditional,2011-04-27
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma,Conditional,2018-10-17
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2018-10-03
Cabozantinib for untreated advanced renal cell carcinoma,Conditional,2018-10-03
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia,Conditional,2018-09-19
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours,Conditional,2018-08-29
Dinutuximab beta for treating neuroblastoma,Conditional,2018-08-22
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine,Conditional,2018-08-08
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer,Conditional,2018-08-08
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2018-08-08
Dupilumab for treating moderate to severe atopic dermatitis,Conditional,2018-08-01
Ocrelizumab for treating relapsing–remitting multiple sclerosis,Conditional,2018-07-25
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer,Conditional,2018-07-18
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy,Rejected,2018-07-04
Beta interferons and glatiramer acetate for treating multiple sclerosis,Rejected,2018-06-27
"Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease",Approved,2011-03-23
502 Bad Gateway,Rejected,2018-06-13
Midostaurin for untreated acute myeloid leukaemia,Conditional,2018-06-13
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma,Conditional,2018-06-13
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,Conditional,2018-06-13
Arsenic trioxide for treating acute promyelocytic leukaemia,Approved,2018-06-13
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy,Conditional,2018-05-16
Tocilizumab for treating giant cell arteritis,Conditional,2018-04-18
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen,Rejected,2018-03-28
Cabozantinib for treating medullary thyroid cancer,Conditional,2018-03-28
Brodalumab for treating moderate to severe plaque psoriasis,Conditional,2018-03-21
Tivozanib for treating advanced renal cell carcinoma,Conditional,2018-03-21
Obinutuzumab for untreated advanced follicular lymphoma,Conditional,2018-03-21
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee,Conditional,2018-03-07
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer,Conditional,2018-03-07
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C,Conditional,2018-02-21
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women,Rejected,2008-10-27
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women,Approved,2008-10-27
Pirfenidone for treating idiopathic pulmonary fibrosis,Conditional,2018-02-06
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer,Rejected,2018-01-31
Ibrutinib for treating relapsed or refractory mantle cell lymphoma,Conditional,2018-01-31
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,Rejected,2018-01-31
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma,Conditional,2018-01-24
Glecaprevir–pibrentasvir for treating chronic hepatitis C,Conditional,2018-01-24
Ceritinib for untreated ALK-positive non-small-cell lung cancer,Conditional,2018-01-24
Golimumab for treating non-radiographic axial spondyloarthritis,Conditional,2018-01-10
"Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",Conditional,2017-12-20
"Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",Conditional,2017-12-20
Naltrexone–bupropion for managing overweight and obesity,Rejected,2017-12-12
Vismodegib for treating basal cell carcinoma,Rejected,2017-11-22
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane,Conditional,2017-07-19
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours,Conditional,2017-11-15
Sarilumab for moderate to severe rheumatoid arthritis,Conditional,2017-11-01
Aflibercept for treating choroidal neovascularisation,Conditional,2017-11-01
Tofacitinib for moderate to severe rheumatoid arthritis,Conditional,2017-10-11
Immunosuppressive therapy for kidney transplant in adults,Rejected,2017-10-11
Immunosuppressive therapy for kidney transplant in children and young people,Rejected,2017-10-11
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee,Conditional,2017-10-04
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma,Conditional,2017-10-04
Reslizumab for treating severe eosinophilic asthma,Conditional,2017-10-04
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer,Approved,2017-03-29
Pembrolizumab for advanced melanoma not previously treated with ipilimumab,Approved,2015-11-25
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy,Conditional,2017-01-11
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab,Approved,2015-10-07
Sorafenib for treating advanced hepatocellular carcinoma,Conditional,2017-09-06
Dimethyl fumarate for treating moderate to severe plaque psoriasis,Conditional,2017-09-06
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer,Conditional,2017-09-06
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck,Approved,2017-08-31
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal),Rejected,2017-08-23
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal),Rejected,2017-08-23
Holoclar for treating limbal stem cell deficiency after eye burns,Conditional,2017-08-16
Pemetrexed for the maintenance treatment of non-small-cell lung cancer,Approved,2010-06-23
Cabozantinib for previously treated advanced renal cell carcinoma,Conditional,2017-08-09
Baricitinib for moderate to severe rheumatoid arthritis,Conditional,2017-08-09
Adalimumab and dexamethasone for treating non-infectious uveitis,Conditional,2017-07-26
Roflumilast for treating chronic obstructive pulmonary disease,Conditional,2017-07-26
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma,Approved,2017-07-26
"Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people",Conditional,2017-07-12
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment,Approved,2017-07-12
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal),Rejected,2017-07-05
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal),Rejected,2017-07-05
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2017-07-05
Etelcalcetide for treating secondary hyperparathyroidism,Conditional,2017-06-28
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease,Approved,2017-06-28
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia,Conditional,2017-06-28
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia,Conditional,2017-06-28
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal),Rejected,2017-05-24
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2017-05-24
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine,Rejected,2017-04-26
Ixekizumab for treating moderate to severe plaque psoriasis,Conditional,2017-04-26
Obeticholic acid for treating primary biliary cholangitis,Conditional,2017-04-26
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal),Rejected,2017-03-29
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal),Rejected,2011-12-14
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal),Rejected,2017-03-22
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal),Rejected,2017-03-22
Elotuzumab for previously treated multiple myeloma (terminated appraisal),Rejected,2017-03-22
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal),Rejected,2017-03-22
Ustekinumab for treating active psoriatic arthritis,Rejected,2015-06-04
Ustekinumab for the treatment of adults with moderate to severe psoriasis,Approved,2009-09-23
Everolimus for advanced renal cell carcinoma after previous treatment,Conditional,2017-02-22
Apremilast for treating active psoriatic arthritis,Conditional,2017-02-22
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,Approved,2017-01-25
Sofosbuvir–velpatasvir for treating chronic hepatitis C,Conditional,2017-01-25
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib,Approved,2017-01-11
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy,Conditional,2016-12-21
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,Conditional,2016-12-21
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,Approved,2016-12-21
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer,Conditional,2016-12-21
"Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia",Rejected,2016-12-21
"Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia",Conditional,2016-12-21
Ticagrelor for preventing atherothrombotic events after myocardial infarction,Approved,2016-12-14
Dapagliflozin in combination therapy for treating type 2 diabetes,Rejected,2013-06-26
Nivolumab for previously treated advanced renal cell carcinoma,Approved,2016-11-23
Dapagliflozin in triple therapy for treating type 2 diabetes,Approved,2016-11-23
Apremilast for treating moderate to severe plaque psoriasis,Conditional,2016-11-23
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,Conditional,2016-10-26
Elbasvir–grazoprevir for treating chronic hepatitis C,Conditional,2016-10-26
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma,Rejected,2016-10-26
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer,Rejected,2016-09-28
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases,Conditional,2016-09-28
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,Conditional,2016-09-28
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,Conditional,2016-09-28
Pegaspargase for treating acute lymphoblastic leukaemia,Approved,2016-09-28
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion,Conditional,2016-09-28
Talimogene laherparepvec for treating unresectable metastatic melanoma,Conditional,2016-09-28
Bosutinib for previously treated chronic myeloid leukaemia,Approved,2016-08-24
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,Approved,2016-08-24
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer,Rejected,2016-08-24
Degarelix for treating advanced hormone-dependent prostate cancer,Conditional,2016-08-24
Trifluridine–tipiracil for previously treated metastatic colorectal cancer,Approved,2016-08-24
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel,Rejected,2016-05-25
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,Conditional,2012-06-27
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts,Rejected,2016-07-27
Nivolumab in combination with ipilimumab for treating advanced melanoma,Approved,2016-07-27
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,Approved,2016-04-27
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia,Conditional,2016-06-22
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia,Conditional,2016-06-22
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,Conditional,2016-06-22
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma,Approved,2016-06-22
Adalimumab for treating moderate to severe hidradenitis suppurativa,Conditional,2016-06-22
"Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes",Rejected,2016-05-25
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction,Approved,2016-04-27
"Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer",Rejected,2016-04-27
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis,Rejected,2016-03-23
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer),Rejected,2001-04-26
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia,Approved,2016-02-24
Nivolumab for treating advanced (unresectable or metastatic) melanoma,Approved,2016-02-18
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis,Conditional,2016-02-01
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,Approved,2016-01-27
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy,Rejected,2016-01-27
Nintedanib for treating idiopathic pulmonary fibrosis,Rejected,2016-01-27
Panobinostat for treating multiple myeloma after at least 2 previous treatments,Approved,2016-01-27
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal),Rejected,2016-01-27
"Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed",Rejected,2016-01-26
Guidance on the use of imatinib for chronic myeloid leukaemia,Approved,2003-10-22
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears,Approved,2015-12-16
Bortezomib for previously untreated mantle cell lymphoma,Approved,2015-12-16
"Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis",Approved,2015-12-16
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy,Rejected,2015-12-16
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C,Conditional,2015-11-25
Vortioxetine for treating major depressive episodes,Rejected,2015-11-25
Ledipasvir–sofosbuvir for treating chronic hepatitis C,Rejected,2015-11-25
Tolvaptan for treating autosomal dominant polycystic kidney disease,Rejected,2015-10-28
Idelalisib for treating chronic lymphocytic leukaemia,Rejected,2015-10-28
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal),Rejected,2015-10-28
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy,Rejected,2015-08-26
"Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)",Rejected,2015-08-26
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism,Approved,2015-08-26
Naloxegol for treating opioid‑induced constipation,Approved,2015-07-22
Aflibercept for treating diabetic macular oedema,Rejected,2015-07-22
"Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",Conditional,2015-07-22
Everolimus for preventing organ rejection in liver transplantation,Rejected,2015-07-22
Secukinumab for treating moderate to severe plaque psoriasis,Rejected,2015-07-22
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal),Rejected,2015-07-22
Omalizumab for previously treated chronic spontaneous urticaria,Rejected,2015-06-08
Vedolizumab for treating moderately to severely active ulcerative colitis,Conditional,2015-06-05
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,Approved,2015-06-04
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia,Rejected,2015-06-02
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome,Approved,2015-03-25
Empagliflozin in combination therapy for treating type 2 diabetes,Rejected,2015-03-25
Rifaximin for preventing episodes of overt hepatic encephalopathy,Approved,2015-03-25
"Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy",Conditional,2015-02-25
Sofosbuvir for treating chronic hepatitis C,Rejected,2015-02-25
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment,Conditional,2015-02-25
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal),Rejected,2015-02-25
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma,Conditional,2012-12-12
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,Approved,2014-12-17
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy,Rejected,2014-11-26
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block,Rejected,2014-11-26
Nalmefene for reducing alcohol consumption in people with alcohol dependence,Approved,2014-11-26
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours,Rejected,2014-11-26
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block,Approved,2005-02-23
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma,Conditional,2014-10-22
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis,Rejected,2014-08-27
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen,Conditional,2014-07-23
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes,Approved,2014-07-23
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma,Conditional,2014-07-23
Canagliflozin in combination therapy for treating type 2 diabetes,Rejected,2014-06-25
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure,Rejected,2014-06-25
Teriflunomide for treating relapsing–remitting multiple sclerosis,Rejected,2014-01-22
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,Conditional,2014-04-23
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation,Approved,2014-04-23
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis,Rejected,2014-03-26
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy,Rejected,2014-03-25
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip,Conditional,2014-02-26
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion,Conditional,2014-02-26
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma,Rejected,2014-02-26
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people,Approved,2013-11-27
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal),Rejected,2013-11-27
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C,Approved,2006-08-23
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C,Approved,2004-01-28
Pazopanib for the first-line treatment of advanced renal cell carcinoma,Approved,2011-02-23
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder,Approved,2013-07-24
Aflibercept solution for injection for treating wet age‑related macular degeneration,Conditional,2013-07-24
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism,Approved,2013-06-26
Mirabegron for treating symptoms of overactive bladder,Rejected,2013-06-26
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer,Rejected,2013-05-22
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer,Rejected,2013-05-22
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal),Rejected,2013-05-22
Omalizumab for treating severe persistent allergic asthma,Conditional,2013-04-24
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures,Rejected,2013-04-24
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis,Rejected,2013-03-27
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal),Rejected,2013-03-27
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract,Rejected,2013-01-23
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal),Rejected,2013-01-23
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma,Conditional,2012-12-12
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal),Rejected,2012-12-12
Dronedarone for the treatment of non-permanent atrial fibrillation,Approved,2010-08-25
Mannitol dry powder for inhalation for treating cystic fibrosis,Approved,2012-11-28
Ivabradine for treating chronic heart failure,Approved,2012-11-28
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours,Rejected,2012-10-24
Alteplase for treating acute ischaemic stroke,Approved,2012-09-26
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer,Rejected,2012-08-22
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,Approved,2012-07-25
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer,Approved,2012-06-27
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine,Rejected,2012-06-27
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2,Rejected,2012-06-27
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation,Approved,2012-05-23
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis,Conditional,2012-04-25
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation,Approved,2012-03-15
Pharmalgen for the treatment of bee and wasp venom allergy,Approved,2012-02-22
Tocilizumab for the treatment of rheumatoid arthritis,Approved,2012-02-22
Rituximab for the first-line treatment of stage III-IV follicular lymphoma,Rejected,2012-01-25
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults,Approved,2012-01-25
"Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy",Rejected,2012-01-25
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer,Rejected,2007-01-24
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis,Rejected,2011-12-14
Fulvestrant for the treatment of locally advanced or metastatic breast cancer,Rejected,2011-12-14
Mifamurtide for the treatment of osteosarcoma,Approved,2011-10-26
Ticagrelor for the treatment of acute coronary syndromes,Approved,2011-10-26
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma,Approved,2011-07-27
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion,Approved,2011-07-27
Agomelatine for the treatment of major depressive episodes (terminated appraisal),Rejected,2011-07-27
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction,Approved,2003-11-26
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer,Rejected,2011-06-29
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs,Approved,2011-06-22
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma,Approved,2011-06-22
"Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease",Rejected,2011-05-25
Golimumab for the treatment of psoriatic arthritis,Conditional,2011-04-27
"Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia",Approved,2011-03-23
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer,Rejected,2011-02-23
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia,Approved,2011-02-23
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years,Approved,2011-01-26
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events,Conditional,2010-12-15
Prucalopride for the treatment of chronic constipation in women,Approved,2010-12-15
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer,Rejected,2010-12-15
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer,Approved,2010-11-24
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours,Rejected,2010-11-24
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours,Rejected,2004-10-27
Denosumab for the prevention of osteoporotic fractures in postmenopausal women,Approved,2010-10-27
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal),Rejected,2010-10-27
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal),Rejected,2010-10-27
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C,Approved,2010-09-22
"Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor",Conditional,2010-08-25
"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis",Rejected,2010-08-25
Capecitabine for the treatment of advanced gastric cancer,Approved,2010-07-28
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer,Approved,2010-07-28
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia,Approved,2010-07-28
Human growth hormone (somatropin) for the treatment of growth failure in children,Approved,2010-05-26
Infliximab and adalimumab for the treatment of Crohn's disease,Approved,2010-05-19
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes,Rejected,2002-09-05
Topotecan for the treatment of relapsed small-cell lung cancer,Rejected,2009-11-25
Topotecan for the treatment of recurrent and stage IVB cervical cancer,Conditional,2009-10-28
Guidance on the use of electroconvulsive therapy,Approved,2003-04-26
Sunitinib for the treatment of gastrointestinal stromal tumours,Approved,2009-09-23
Pemetrexed for the first-line treatment of non-small-cell lung cancer,Conditional,2009-09-23
Alitretinoin for the treatment of severe chronic hand eczema,Approved,2009-08-26
"Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma",Rejected,2009-08-26
Tenofovir disoproxil for the treatment of chronic hepatitis B,Approved,2009-07-22
Rituximab for the first-line treatment of chronic lymphocytic leukaemia,Rejected,2009-07-22
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults,Approved,2009-04-22
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma,Approved,2009-03-25
"Amantadine, oseltamivir and zanamivir for the treatment of influenza",Rejected,2009-02-25
Machine perfusion systems and cold static storage of kidneys from deceased donors,Rejected,2009-01-28
Infliximab for acute exacerbations of ulcerative colitis,Approved,2008-12-17
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin,Rejected,2008-10-22
Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults,Approved,2008-09-24
"Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza",Rejected,2008-09-24
Routine antenatal anti-D prophylaxis for women who are rhesus D negative,Approved,2008-08-27
Entecavir for the treatment of chronic hepatitis B,Approved,2008-08-27
Telbivudine for the treatment of chronic hepatitis B,Rejected,2008-08-27
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus,Rejected,2008-07-23
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal),Rejected,2008-06-25
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal),Rejected,2008-06-25
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck,Approved,2008-06-25
Adalimumab for the treatment of adults with psoriasis,Approved,2008-06-25
Structural neuroimaging in first-episode psychosis,Rejected,2008-02-27
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma,Approved,2008-02-27
Infliximab for the treatment of adults with psoriasis,Approved,2008-01-23
Pemetrexed for the treatment of malignant pleural mesothelioma,Approved,2008-01-23
Bortezomib monotherapy for relapsed multiple myeloma,Approved,2007-10-23
Stapled haemorrhoidopexy for the treatment of haemorrhoids,Approved,2007-09-26
Pemetrexed for the treatment of non-small-cell lung cancer,Rejected,2007-08-22
Varenicline for smoking cessation,Approved,2007-07-25
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma,Rejected,2007-06-27
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia,Rejected,2007-02-28
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy,Rejected,2007-01-24
Methadone and buprenorphine for the management of opioid dependence,Rejected,2007-01-24
Naltrexone for the management of opioid dependence,Approved,2007-01-24
Gemcitabine for the treatment of metastatic breast cancer,Approved,2007-01-24
Laparoscopic surgery for colorectal cancer,Approved,2006-08-23
Etanercept and efalizumab for the treatment of adults with psoriasis,Rejected,2006-07-26
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer,Rejected,2006-06-28
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer,Rejected,2006-04-26
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B,Approved,2006-02-22
HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries),Rejected,2005-07-27
Guidance on the use of paclitaxel in the treatment of ovarian cancer,Approved,2003-01-22
Laparoscopic surgery for inguinal hernia repair,Approved,2004-09-22
Tacrolimus and pimecrolimus for atopic eczema,Rejected,2004-08-25
Frequency of application of topical corticosteroids for atopic eczema,Approved,2004-08-25
"Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia",Approved,2004-04-28
Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding,Rejected,2004-04-28
Pre-hospital initiation of fluid replacement therapy in trauma,Approved,2004-01-28
Guidance on the use of liquid-based cytology for cervical screening,Approved,2003-10-22
Human growth hormone (somatropin) in adults with growth hormone deficiency,Conditional,2003-08-27
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer,Approved,2003-05-27
Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction,Approved,2002-10-30
Guidance on the use of ultrasound locating devices for placing central venous catheters,Rejected,2002-10-04
Guidance on the use of trastuzumab for the treatment of advanced breast cancer,Approved,2002-03-15
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia,Approved,2001-09-26
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease,Approved,2001-01-23
Guidance on the extraction of wisdom teeth,Rejected,2000-03-27
